

## OXIDATIVE SPECTROPHOTOMETRIC DETERMINATION OF DRUGS IN PHARMACEUTICAL FORMULATION USING N-BROMOSUCCINAMIDE AS AN OXIDANT AND SAFRANIN-O DYE.

Munnuru Pandurangam and A. Panasareddy\*

Department of Chemistry, University College of Science, Osmania University, Hyderabad-500007, India.

Article Received on  
06 May 2018,

Revised on 26 May 2018,  
Accepted on 16 June 2018

DOI: 10.20959/wjpr201813-12696

### \*Corresponding Author

**A. Panasareddy**

Department of Chemistry,  
University College of  
Science, Osmania  
University, Hyderabad-  
500007, India.

### ABSTRACT

A simple, sensitive and selective method has been developed for the spectrophotometric determination of drugs, viz., Moxifloxacin, Ramipril, Samaritan, Trimetazidine and Lacosamide. The proposed method involves the addition of excess NBS of known concentration in the presence of acidic medium and the unreacted NBS is determined by the measurement of the decrease in the absorbance of the dye safranin-o blue ( $\lambda_{\max}$  532 nm). The colored species in acidic medium, reactants are allowed to react and the unreacted NBS is estimated by the measurement in the decrease in the absorbance of the safranin-o dye ( $\lambda_{\max}$  532 nm). This method has been validated in terms of guidelines of ICH and applied to the quantification of selected drugs in

bulk and dosage forms.

**KEYWORDS:** Spectrophotometry, Drugs, NBS, Safranin-o, Quantification, Validation.

### INTRODUCTION

#### Moxifloxacin [MOX]

Moxifloxacin (1-cyclopropyl-7-(2, 8- diazobicyclo [4.3.0] nonane)-6-fluoro-8- methoxy-1, 4-dihydro-4- oxo-3-quinoline carboxylic acid) (Figure 1) is a fourth generation fluoroquinolone. The determination of MOX is not yet described in any pharmacopoeias. Therefore, a simple<sup>[1,2]</sup>, accurate method is required for their determination in pharmaceutical formulations. A survey of literature revealed that MOX has been determined in biological fluids or pharmaceutical products by HPLC<sup>[3]</sup> and potentiometric method.<sup>[4]</sup>

**Ramipril (RAM)**

Ramiprilis (2S, 3aS, 6aS)-1-[(S)-2-[[[(S)-1-(ethoxycarbonyl)-3-phenylpropyl] amino] propanoyl] octahydrocyclopenta[b]pyrrole-2- carboxylic acid. It is an angiotensin converting enzyme (ACE) inhibitor. ACE inhibitors are used to treat hypertension and congestive heart failure. They act by lowering the production of angiotensin II, thereby relaxing arterial muscles while at the same time enlarging the arteries, allowing the heart to pump blood more easily, and increasing blood flow due to more blood being pumped into and through larger passage ways.<sup>[5]</sup> The British Pharmacopoeia recommends a liquid chromatographic (LC)<sup>[6]</sup> method for its determination in raw material and in dosage forms.<sup>[7]</sup>

**Sumatriptan Succinate [SUM]**

Sumatriptan succinate is a selective 5-hydroxytryptamine<sub>1</sub> receptor subtype agonist is chemically designated as 3-[2-(dimethyl amino) ethyl]-N-methyl-indole-5-methane sulfonamide succinate (1:1). This drug used in the treatment of migraine attacks. Literature survey reveals many methods for estimation of SUM<sup>[8,9]</sup> and very few methods are available for simultaneous determination by UV<sup>[10,11]</sup>, HPTLC<sup>[12]</sup> and HPLC.<sup>[13,15]</sup>

In this communication, a new simple, rapid and precise HPLC method has been reported for simultaneous determination of SUM which can be used for its routine analysis in normal laboratories.





**Trimetazidine [TDH]**


Tramadol Hydrochloride is chemically known as Tramadol [(±) Trans - 2 - (dimethylaminomethyl) - 1 - (3-methoxy- phenyl)-cyclohexanol hydrochloride]. It is a centrally acting opioid analgesic.<sup>1</sup> Tramadol and its metabolite (+)-Odes methyl-tramadol (M1) are weak agonists of the  $\mu$  opioid receptor. (+)-Tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake.

Various methods have been reported for the determination of tramadol in bulk, pharmaceutical preparations, biological fluids and hair including spectrophotometry<sup>[16,19]</sup>, high performance liquid chromatography (HPLC)<sup>[20,22]</sup>, potentiometry<sup>[23]</sup> and chromatography.<sup>[24]</sup>

**Lacosamide [LAC]**

Lacosamide is chemically (R)-2-acetamido-N-benzyl-3-methoxy propionamide used to treat partial-onset seizures in people with epilepsy who are at least 17 years old. It selectively enhances slow inactivation of voltage-gated sodium channels and modulates collapsin response mediator protein-2 (CRMP-2) involved in neuronal differentiation and control of axon outgrowth.<sup>[1]</sup> The literature survey revealed that there were some analytical methods reported for lacosamide like HPLC.<sup>[25,27]</sup> The review prompted us to develop a simple, precise and economic HPTLC<sup>[28]</sup> method for the estimation of Lacosamide in bulk and in tablet dosage form.

**Structures of the drugs****[Fig.1] Sumatriptan succinate.****[Fig.2] Moxifloxacin.****[Fig.3] Ramipril.****[Fig.4] Lacosamid.**



[Fig.5] Trimetazidine.

## MATERIALS AND METHODS

### Instrument

The analysis of the drugs were recorded on Shimadzu 140 double beam spectrophotometer as well as on Elico 210 UV- Visible double beam & Elico 159 UV- Visible single beam spectrophotometers using matched pair of Quartz cells of 10mm path length.

### Materials

Stock solution of NBS (0.5%) was prepared by dissolving 0.5gm NBS in 100mL standard flask with double distilled water and this Stock solution of NBS was further diluted to get the working concentration.

Safranin-o stock solution (0.02%) was prepared by dissolving in distilled water. The dye solution was further diluted to get the working concentration.


The pharmaceutical grade drugs were supplied by Hetero Drugs Pvt. Limited, Hyderabad. A stock solution of drug was prepared by dissolving accurately weighed 20mg of pure drug in water and diluting to 100mL in a volumetric flask with distilled water. The solution was diluted stepwise to get working concentrations.

### Assay Procedure

Aliquots of pure drug solution (1 to 7mL) was transferred to a series of 10mL calibrated flask and to this 1mL of 2M H<sub>2</sub>SO<sub>4</sub> was added, followed by 1mL of NBS solution (0.5%). and the solution was shaken for 15 min. The 1mL of 0.02% safranin-o solution was added to each

flask, diluted to the mark with water and the absorbance of solution was measured at 532 nm against a reagent blank.

Calibration curves [figure. 6] were constructed for all the drugs by plotting the absorbance versus the concentration of drugs. The absorbance data was collected for six replicate experiments and absorbance to concentration ratio called the relative response was determined.



### Procedure for Assay of Pure Drug

To test the accuracy and precision of the methods developed pure sample solutions containing drug in the Beer's law limit were chosen. For this study 20,40 and 60 µg ml<sup>-1</sup> of MOX; 10, 20, and 30 µg ml<sup>-1</sup> of RAM; 20, 30 and 40 µg ml<sup>-1</sup> of SUM; 10, 20 and 30 µg ml<sup>-1</sup> of TRI; 2, 4 and 6 µgml<sup>-1</sup> of LACO have been taken. The concentration chosen and recovery are tabulated in table 2. For this purpose standard deviation method also adapted.

### Procedure For Tablets

#### 1. Sumatriptan Succinate

Ten tablets of sumatriptan succinate [Suminat-25 and Suminat-50] each containing 25 mg of SUM were weighed and finely powdered in a mortar. A quantity of powder equivalent to 20 mg of SUM was weighed accurately and dissolved in 100 ml of double distilled water, and sonicated for 20 min. It was used as stock sample solution and was further diluted with the same solvent to get working standard solution.

## 2. Ramipril

Ten tablets of ramipril [Cardiopril 5mg] were weighed and grounded. A quantity equivalent to 20mg of RAM was transferred into a 100mL calibrated flask, mixed well and filtered using a filter paper. First 10mL portion of the filtrate was discarded and a suitable aliquot of the subsequent portion was diluted appropriately to get required concentration and the assay was completed according to the procedure described above.

## 3. Moxifloxacin

Ten tablets of drug [Mahaflox 400mg] were weighed and grounded and transferred into a 100mL calibrated flask and added 30mL of distilled water followed by sonication for 15 minutes. The solution was finally made up to 100mL. It was used as stock sample solution and was further diluted with the distilled water to get working concentration solution for assay.

## 4. Trimetazidine

Four tablets [Cardimax 60 mg] were weighed and grounded. The powder equivalent to 10mg TRI was stirred well with methanol, sonicated about 30 minutes. The solution was filtered through Whitman filter paper in a 100mL volumetric standard flask and the residue was washed well with methanol for complete recovery of the drug and methanol was evaporated. The residue was dissolved in 100mL of distilled water and it was further diluted to get required concentration for the analysis of the drug.

## 5. Lacosamide

Ten tablets [Lacoste 100mg] were powdered and equivalent to about 10mg of LAC had been taken in to a 100mL of volumetric flask and added about 30mL of methanol, sonicated For 20 min and filtered through Whitman filter paper No 42. The residue was washed thrice with methanol for complete recovery of drug and methanol was evaporated. The residue was dissolved in 100mL of distilled water. It was used as stock sample solution. The aliquot portions of this stock solution were further diluted with distilled water to get the final concentration required for the determination of the drug.

## RESULTS AND DISCUSSION

### Method Development

The proposed spectrophotometric method is indirect and is based on the determination of the excess of NBS after allowing the reaction between drug and a measured amount of NBS to be

complete. The excess of NBS was determined by reacting it with a fixed amount of Safranin-o dye. The methods make use of bleaching action of NBS on the dye, the decolouration being caused by the oxidative destruction of the dyes. Drug when added in increasing concentrations to a fixed concentration of NBS, consumes the latter proportionally and there occurs a concomitant fall in the concentration of NBS. When a fixed concentration of dye is added to decreasing concentrations of NBS, a concomitant increase in the concentration of dye is obtained. Consequently, a proportional increase in the absorbance at the respective  $\lambda_{\max}$  is observed with increasing concentration of drug.

Preliminary experiments were conducted to determine the maximum concentrations of Safranin-o spectrophotometric ally by measuring the absorbance of their acidic solutions at their respective  $\lambda_{\max}$  and the upper limits were found to be 0.02% for safranin-o. NBS concentration of 0.5% was found to bleach the color due to 0.02% of Safranin-0. Hence different amounts of drug reacted with 0.5% NBS in this method before determining the residual NBS as described under the respective procedure.

### **Analytical Data**

A linear correlation was found between absorbance at  $\lambda_{\max}$  and concentration of all drugs in the ranges given in table 1. Regression analysis of the Beer's law data using the method of least squares was made to evaluate the slope (b), intercept (a) and correlation coefficient (r) for each system and the values are presented in table 1. The optical characteristics such as Beer's law limits and Sandell sensitivity values for these methods are given in table 1. The limits of detection (LOD) and quantitation (LOQ) calculated according to ICH guidelines<sup>[15]</sup> are also presented in table 1 and reveal the very high sensitivity of the methods.

$$\text{LOD} = 3.3S_a/b$$

$$\text{LOQ} = 10S_a/b.$$

Where  $S_a$  = standard deviation of the intercept (n = 6)

b = slope of Calibration plot.

### **Precision and Accuracy**

Intra-day precision was assessed from the results of six replicate analyses on pure drug solution. The mean values and relative standard deviation (RSD) values for replicate analyses at three different levels (amounts/concentrations) were calculated. To evaluate the inter-day precision, analysis was performed over a period of five days, preparing all solutions afresh each day.

The accuracy of the methods was determined by calculating the percentage deviation observed in the analysis of pure drug solution and expressed as the relative error. Table 2 summarizes the intra-day precision and accuracy data for the assay of pure drugs solution by the proposed methods.

### Robustness and Ruggedness

To evaluate the robustness of the methods, volume of Sulphuric acid was slightly altered. The reaction time (after adding NBS, time varied was  $15 \pm 2$  min) and the time after addition of dyes slightly changed. To check the ruggedness, analysis was performed by three different analysts and on three different spectrophotometers by the same analyst.

### Application to Formulations

The proposed methods are applied to the determination of drugs in tablets. The results in Table 3 showed that the methods are successful for the determination of drugs and excipients in the dosage forms do not interfere. The results are compared to the available validated reported<sup>[16,20]</sup> methods on each drug and the results agree well with the claim and also are in agreement with the results obtained by the literature method.

**Table 1: Analytical and regression parameters of spectrophotometric method.**

Parameter	MOX	RAM	SUM	TRI	LAC
$\lambda_{\max}$ , nm	532	532	532	532	532
Beer's law limits $\mu\text{g mL}^{-1}$	20-140	10-70	20-80	10-70	2-14
Molar absorptivity, $\text{L mol}^{-1} \text{cm}^{-1}$	$4.75 \times 10^3$	$4.86 \times 10^3$	$3.67 \times 10^3$	$4.92 \times 10^3$	$1.55 \times 10^4$
Sandell sensitivity $\mu\text{g cm}^{-2}$	0.2	0.08	0.1	0.07	0.02
Limit of detection $\mu\text{g mL}^{-1}$	2.286	1.373	1.725	3.081	0.7092
Limit of quantification $\mu\text{g mL}^{-1}$	6.928	4.16	5.281	9.33	2.14
Intercept, (a)	0.1	-0.005	0.094	0.011	0.022
Slope, (b)	0.005	0.012	0.01	0.013	0.049
Correlation coefficient, (r)	0.997	0.997	0.970	0.995	0.999
Standard deviation of intercept ( $\sigma$ )	0.0034	0.004	0.0052	0.012	0.027
Regression equation, Y	$0.005X+0.1$	$0.012X-0.005$	$0.010X+0.094$	$0.013X-0.011$	$0.049X+0.022$

**Table 2: Determination of accuracy and precision of the methods on pure drug samples.**

Drug	Taken ( $\mu\text{g mL}^{-1}$ )	Found ( $\mu\text{g mL}^{-1}$ )	Error (%)	Recovery (%)	RSD (%)	Proposed method Mean $\pm$ SD
MOX	20	19.98	0.10	99.9	0.0750	99.9375 $\pm$ 0.075
	40	40.02	-0.05	100.05		
	60	59.94	0.10	99.9		
RAM	10	9.98	0.20	99.8	0.1398	99.92 $\pm$ 0.1396
	20	19.96	0.20	99.8		
	30	30.01	0.03	100.03		
SUM	20	19.98	0.10	99.9	0.100203	99.92 $\pm$ 0.1001
	30	29.94	0.20	99.8		
	40	39.98	0.05	99.95		
TRI	10	9.96	0.4	99.6	0.188	99.87 $\pm$ 0.1887
	20	19.98	0.1	99.9		
	30	30.01	0.033	100.03		
LAC	2	1.96	2	98	1.119	99.39 $\pm$ 1.112
	4	4.01	0.25	100.25		
	6	6.02	0.33	100.33		

**Table 3: Results of Assay of Tablets by the Proposed Method and Statistical Evaluation.**

Tablets	Taken ( $\mu\text{g mL}^{-1}$ )	Found ( $\mu\text{g mL}^{-1}$ )	er (%)	Recovery (%)	RSD (%)	Proposed method Mean $\pm$ SD	Reference method mean $\pm$ SD	Student's t-test	F-test
MOX [Suminat]	15	14.98	0.133	99.566	0.090	99.89 $\pm$ 0.090	100.23 $\pm$ 0.8926	2.1965	0.0102
	24	23.95	0.208	99.79					
	35	35	0.00	100.00					
RAM [Cardipril]	06	5.94	1.00	99.00	0.470	99.65 $\pm$ 0.468	99.98 $\pm$ 0.8134	0.8994	0.3320
	14	13.95	0.357	99.64					
	26	25.98	0.076	99.92					
SUM [Mahaflox]	15	14.96	0.266	99.73	0.144	99.93 $\pm$ 0.1446	99.86 $\pm$ 0.2456	0.8680	0.3466
	25	24.98	0.080	99.92					
	30	30.01	0.033	100.033					
TRI [Cardimax]	8	7.98	0.250	99.75	0.096	99.82 $\pm$ 0.0964	100.23 $\pm$ 0.896	2.173	0.0115
	16	15.98	0.125	99.87					
	24	23.94	0.25	99.75					
LAC [Lacoste]	3	2.95	1.666	98.33	0.769	99.40 $\pm$ 0.0764	100.32 $\pm$ 0.8936	0.2669	0.7335
	5	4.98	0.4	99.6					
	7	7.01	0.14	100.14					

## CONCLUSION

These are simple, rapid, and cost-effective methods for the determination of drugs have been developed and validated. The proposed methods are more sensitive methods and the methods rely on the use of simple and cheap chemicals and techniques but provide sensitivity

comparable to that achieved by sophisticated and expensive technique like HPLC. Thus, they can be used as alternatives for rapid and routine determination of bulk sample and tablets.

### ACKNOWLEDGEMENTS

The authors are thankful to the Head, Department of Chemistry, Osmania University, and Hyderabad-500007 for providing facilities. One of the authors M.PANDURANGAM is thankful to CSIR for award of SRF.

### REFERENCES

1. Vandana, Alok Chaudhary. "A novel and validated UVspectrophotometric method for estimation of moxifloxacin hydrochloride in tablets". African journal of pharmaceutical sciences and pharmacy, 2010; 130-135.
2. Misra M , Misra A.K , Zope P, Panpalia G. M , Dorle A. K. "simple and validated uv-spectroscopic method for estimation of moxifloxacin.hcl in bulk and formulation". Journal of Global Pharm Technology, 2010; 2(6): 21-27.
3. S. Tatar Ulu. "High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma". Journal of Pharmaceutical and Biomedical Analysis, 2007; 43(1): 320–324.
4. Malaz Osman Idress<sup>1</sup>, Abdalla A. Elbashir<sup>1\*</sup> and Omer Nur. "Potentiometric Determination of Moxifloxacin by ZnO Nanorodes Modified ion Selective Electrode" Pharm Anal Acta., 2017; 8(10): 566.
5. M. Purushotham reddy\*, P. Raveendra reddy and N. Rami reddy. A simple spectrophotometric method for the assay of ramipril in pharmaceutical formulations. Int. J. Chem. Sci., 2011; 9(2): 779-783 ISSN 0972-768x.
6. k.Veeran Gowda<sup>a</sup> Uttam Mandal<sup>a</sup> P.Senthamil Selvan<sup>a</sup> W.D.Sam Solomon<sup>a</sup> Animesh Ghosh<sup>a</sup> Amlan Kanti Sarkar<sup>a</sup> Sangita Agarwal<sup>a</sup> T.Nageswar Rao<sup>b</sup> Tapan Kumar Pal<sup>a</sup>. Liquid chromatography tandem mass spectrometry method for simultaneous determination of metoprolol tartrate and ramipril in human plasma. Journal Volume 858, Issues 1–2.
7. OE Afieroho<sup>1\*</sup>, O Okorie<sup>2</sup> and TJN Okonkwo. A Spectrophotometric Method for the Determination of Ramipril in Solid Dosage Forms. Tropical Journal of Pharmaceutical Research, April 2012; 11(2): 275-279.
8. Kumar Nayak, Sunil Kumar Swain, Susanta Kumar Panda, Kanhu Charana Sahu: Method Development and Validation of Sumatriptan in Bulk and Pharmaceutical Dosage Forms

- by UV Spectrophotometric Method. *International Journal of Pharmaceutical & Biological*, 2011; 2(4): 1100-1105.
9. Bebawy LI, Moustafa AA, Abo Talib NF, Stability-indicating methods for the determination of Sumatriptan succinate. *J Pharm Biomed Anal*, 2003; 32: 1123-1133.
  10. Haque T, Talukder MU, Fatema SL, Kabir AKL: Simultaneous Estimation of Naproxen and Ranitidine HCl by Using UV Spectrophotometer. *Stamford J. Pharm. Sci.*, 2008; 1: 18-24.
  11. Gondalia RP, Dharamsi AP: Spectrophotometric simultaneous estimation of naproxen sodium and sumatriptan succinate in tablet dosage forms. *Int. J. Res. Pharm. Biomed. Sci.*, 2010; 1: 24-26.
  12. Gondalia Riddhi, Dharamsi Abhay: HPTLC Method for Simultaneous Determination of Naproxen Sodium and Sumatriptan Succinate in Pharmaceutical Dosage Form. *International Journal of Pharmaceutical Sciences and Research*, 2011; 2(1): 116-120.
  13. Vishwanathan K, Bartlett MG, and Stewart JT: Determination of ant migraine compounds rizatriptan, zolmitriptan, naratriptan and Sumatriptan in human serum by liquid chromatography/electro spray tandem mass spectrometry. *Rapid Commun Mass Spectrum*, 2000; 3: 168-172.
  14. Kumar R, Singh P, Singh H: Development and Validation of RPHPLC Method for Simultaneous Estimation of Naproxen and Pantoprazole in Pharmaceutical Dosage Form. *Int. J. Pharm. Res. Development*, 2011; 12: 227-232.
  15. Monser L, Darghouth F: Simultaneous determination of Naproxen and related compounds by HPLC by using porous graphite carbon column. *J. Pharm. Biomed. Anal.*, 2003; 32: 1087-1092.
  16. Bader, Nabil; El-Awami, Hala; Aljouidi, Awatif; El-Werfaly, Marwa. Spectrophotometric determination of Tramadol Hydrochloride and diclofenac sodium in pharmaceuticals and environmental samples. *Pharmacia Sinica.*, 2013; 4(5): 10-16.
  17. Vasava, Daxa L; Parmar, Shraddha J.; Patel, Bhavna A. Development and validation of first order derivative spectrophotometric method for simultaneous estimation of Tramadol Hydrochloride and Diclofenac sodium in bulk and synthetic mixture. *Journal of Chemical and Pharmaceutical Research*, 2013; 5(5): 213-218.
  18. Vinay, Kanakapura B.; Revenasiddappa, Hosakere D.; Abdulrahman, Sameer A. M. Sensitive spectrophotometric determination of Tramadol Hydrochloride in pharmaceuticals using Folin-Ciocalteu's reagent. *Turkish Journal of Pharmaceutical Sciences*, 2013; 10(1): 57-68.

19. Krishna, L. Mohan; Reddy, P. Jayachandra; Reddy, V. Jaya Sankar; Rao, K. V. S. Prasada. Spectrophotometric determination of tramadol hydrochloride using quinines. *Journal of the Institution of Chemists.*, 2012; 84(4): 111-113.
20. Aysel Küçük, Yücel Kadioğlu. Determination of tramadol hydrochloride in ampoule dosage forms by using UV spectrophotometric and HPLC-DAD methods in methanol and water media. *IL Farmaco.*, 2005; 60(2): 163–169.
21. Gu Y, Fawcett JP. Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci.*, 2005; 821(2): 240-3.
22. Qu L, Feng S, Wu Y, Wu Y. HPLC method for determination of tramadol hydrochloride in human plasma. *Sichuan Da Xue Bao Yi Xue Ban.*, 2003; 34(3): 574-5.
23. Hazem M. Abu Shawish, Ayoub R. Al-Dalou, Nasser Abu Ghalwa and Anwar A. Abou Assi. Potentiometric Sensor for Determination of Tramadol Hydrochloride in Pharmaceutical Preparations and Biological Fluids. *Pharmaceutical Analytical Acta*, 2010; 4172: 2153-2435.
24. Muss Hoff F, Madea B, Stuber F, and Stamer UM. Enantiomer determination of tramadol and O-desmethyltramadol by liquid chromatography- mass spectrometry and application to postoperative patients receiving tramadol. *J Anal Toxicol*, 2006; 30(7): 463-7.
25. Chakravarthy V. and Gowri Sankar D. “Development and Validation of RP-HPLC method for estimation of Lacosamide in bulk and its Pharmaceutical formulation”. *Rasayan J. Chem.*, 2011; 4(3): 666- 672.
26. Chhalotiya U., Bhatt K., Shah D., Baldania S. and Patel J.” Stability-Indicating Liquid Chromatographic Method for Quantification of New Anti-Epileptic Drug Lacosamide in Bulk and Pharmaceutical Formulation”.
27. Vudagandla, S., Rao D., Maheswari U., Das S., Krishnaiah A., Development and validation of a stability-indicating RP – HPLC method for determination of lacosamide, *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 2011; 2(4): 1-11.
28. S.A.Kamdar, V.M. Vaghela, P.A. Desai. “Development and Validation of HPTLC Method for Estimation of Lacosamide in Bulk Drug and in Tablet Dosage Form”. *International Journal of Chem Tech Research CODEN (USA): IJCRGG ISSN: 0974-4290*, 4(3): 1193-1197.